LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment…
Month: May 2022
Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO),…
Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Cash position bolstered through debt financing to support operations into the fourth quarter of 2023…
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma…
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to…
Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) — Shape Therapeutics® Inc. the RNA technology company advancing programmable…
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears…
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology…
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
–Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product…
Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C., May 12, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq:VTVT) today reported…
Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights
– Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022…
Neuronetics Reports First Quarter 2022 Financial and Operating Results
MALVERN, Pa., May 12, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical…
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance…
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
– Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line…
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic;…
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated…
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported…
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
– BridgeBio is eligible to receive up to $905 million, including an upfront payment of…
Aleafia Health Announces Agreement to Amend Convertible Debentures and Equity Financing of $5.6 Million
Transforms the company’s balance sheet with an equity financing to fund growth and a favourable…